Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.

ABSTRACT:

Background

People living with HIV might have a poor or delayed response to vaccines, mainly when CD4 cell counts are low, and data concerning COVID-19 vaccines in this population are scarce. This prospective cohort study assessed the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine CoronaVac in people with HIV compared with people with no known immunosuppression.

Methods

In this prospective cohort study, adults (aged ≥18 years) living with HIV who were regularly followed up at the University of Sao Paulo HIV/AIDS outpatient clinic in Sao Paulo, Brazil, were included in the study. Eligibility for people with HIV was independent of antiretroviral use, HIV viral load, or CD4 cell count. Adults with no known immunosuppression with CoronaVac vaccination history wer

SUBMITTER: Netto LC 

PROVIDER: S-EPMC8942475 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature